Safety Studies Should Be Required To Retain Celebrex, Bextra Approval – Researcher
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised approval standards for COX-2 inhibitors still in development should be extended to marketed drugs "as a condition of their retention of approval," Penn researcher FitzGerald tells FDA advisory committee. FitzGerald says Vioxx safety signal is a class effect, calls Pfizer's argument that it is restricted to rofecoxib an "off-target fantasy."
You may also be interested in...
FDA To Act On COX-2 Committee Input Within "Next Few Weeks"
In remarks to the Arthritis Drugs/Drug Safety & Risk Management advisory committee meeting, CDER Acting Director Galson says the agency will take "rapid" action on the panel's recommendations.
Pfizer Celebrex Safety Representations Draw Cmte. Skepticism
Advisory committee members cite concerns with celecoxib studies that used active comparators instead of long-term placebo controls. Pfizer's presentation highlights the company's belief that Celebrex offers an improved gastrointestinal profile, but similar cardiovascular profile, compared to other NSAIDs.
FDA To Act On COX-2 Committee Input Within "Next Few Weeks"
In remarks to the Arthritis Drugs/Drug Safety & Risk Management advisory committee meeting, CDER Acting Director Galson says the agency will take "rapid" action on the panel's recommendations.